ReutersBig.gif  
Back grey_arrow_rt.gif
 
 
WHO, Boehringer Back German AIDS Drug Despite Fears
 
 
  Reuters
Jan 20, 2005
Sitaraman Shankar; James Macharia
 
On Thursday, the World Health Organization said it continues to back the use of Boehringer Ingelheim's Viramune (nevirapine), a drug used for preventing mother-to-child HIV transmission and part of a subsidized triple AIDS drug cocktail used as continuous therapy. The announcement came one day after the US Food and Drug Administration issued a warning that nevirapine could cause liver damage.
 
"We are aware of the toxicity profile [of nevirapine], but at the moment we believe the benefits outweigh any problems," said Charles Gilks, director of WHO's AIDS treatment and prevention scale-up team.
 
German drug maker Boehringer said it would continue to offer nevirapine free of charge to poor countries for preventing mother-to-child HIV transmission. "There is no consequence for our donation or for supply of the drug for continuous treatment at reduced prices in developing countries," said a company spokesperson. "We do not expect any major effects on the behavior of doctors or on our sales as a result of the FDA warning," she said, adding that Boehringer was in discussions with European regulators over the drug's labeling in Europe.
 
According to FDA, cases of liver damage that produce a rash, fever or other symptoms were more common with nevirapine than with other AIDS drugs. FDA said doctors should weigh risks and benefits before prescribing the drug.
 
"This is a formalization of something known in the medical community," said Daniel Berman, coordinator of Doctors Without Borders' Campaign for Access to Essential Medicines. "All of the drugs have side effects and should be monitored at the beginning of treatment. Other drugs have other issues, none of them is perfect."
 

 
Copyright © 2004 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
 
 
 
 
  icon paper stack View Older Articles   Back to Top   www.natap.org